Amlogenyx is a novel gene therapeutics company that focuses on developing lysosome-based treatments for Alzheimer's disease.
Amlogenyx has raised $10.0M in total funding. The most recent round was Convertible Note. The last funding was announced in July 2026.
Amlogenyx's investors include Ultragenyx Pharmaceutical, GordonMD Global Investments.
Amlogenyx is headquartered in Somerville, United States.
Amlogenyx is a novel gene therapeutics company that focuses on developing lysosome-based treatments for Alzheimer's disease.
Amlogenyx is at the Convertible Note stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Amlogenyx — Funding & Investors." VCBacked, July 8, 2026, https://www.vcbacked.co/company/amlogenyx. Accessed September 30, 2026.
VCBacked. (2026). Amlogenyx — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/amlogenyx
{{cite web |title=Amlogenyx — Funding & Investors |url=https://www.vcbacked.co/company/amlogenyx |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated